Skip to content
10-Q

Quarterly Report

EMERGENT BIOSOLUTIONS INC. EBS

0001367644-25-000124

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 30, 2025 54.28M sh
Long Term Debt Q1 2025 · Mar 31, 2025 $665.7M
Long Term Debt Q1 2025 · Dec 31, 2024 $663.7M
Current Liabilities Q1 2025 · Mar 31, 2025 $111.9M
Current Liabilities Q1 2025 · Dec 31, 2024 $162.4M
Total Liabilities Q1 2025 · Mar 31, 2025 $873.4M
Total Liabilities Q1 2025 · Dec 31, 2024 $906.9M
Current Assets Q1 2025 · Mar 31, 2025 $706.8M
Current Assets Q1 2025 · Dec 31, 2024 $598.7M
Total Assets Q1 2025 · Mar 31, 2025 $1.43B
Total Assets Q1 2025 · Dec 31, 2024 $1.39B
Cash And Equivalents Q1 2025 · Dec 31, 2024 $99.5M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $78.5M
Shares Diluted Q1 2025 · Mar 31, 2024 52.2M sh
Capex Q1 2025 · Mar 31, 2024 $10.8M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$62.6M
Stockholders Equity Q1 2025 · Mar 31, 2024 $663.9M
Stockholders Equity Q1 2025 · Dec 31, 2023 $649.3M
Eps Diluted Q1 2025 · Mar 31, 2024 $0.17
Eps Basic Q1 2025 · Mar 31, 2024 $0.17
Sga Expense Q1 2025 · Mar 31, 2024 $84.7M
Rd Expense Q1 2025 · Mar 31, 2024 $15.1M
Net Income Q1 2025 · Mar 31, 2024 $9M
Operating Income Q1 2025 · Mar 31, 2024 $39.8M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $144.6M
Revenue Q1 2025 · Mar 31, 2024 $300.4M